Skip to content

A Study on Single Center Stroke Reperfusion Registration Based on Spatial Integration and Structured Cases

A Study on Single Center Stroke Reperfusion Registration Based on Spatial Integration and Structured Cases

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400092926
Enrollment
Unknown
Registered
2024-11-26
Start date
2024-12-01
Completion date
Unknown
Last updated
2024-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute ischemic stroke

Interventions

Case series:NA

Sponsors

Beijing Daxing District People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: Continuous inclusion of stroke greenway patients who visited our hospital from June 1, 2024 to December 31, 2025. Inclusion criteria: (1) Age >=18 years old; (2) Acute ischemic stroke; (3) Plan to undergo intravenous thrombolysis, bridging endovascular treatment, or direct endovascular treatment; (4) The patient or their legal representative signs an informed consent form.

Exclusion criteria

Exclusion criteria: Exclusion criteria: (1) Head CT indicates intracranial hemorrhagic disease; (2) Direct intravascular treatment reveals thrombotic autolysis, only cerebral angiography is performed; (3) Individuals with coagulation disorders, thrombocytopenia, a history of systemic hemorrhage, or severe liver and kidney diseases, with absolute contraindications for intravenous thrombolysis or endovascular treatment; (4) Having serious cardiovascular and pulmonary diseases, the researchers believe that it is not suitable to participate in this study; (5) Patients with an expected lifespan of less than 3 months or unable to complete the study due to other reasons; (6) Pregnant or lactating women; (7) Individuals who are unable to complete this study due to mental illness, cognitive or emotional disorders.

Design outcomes

Primary

MeasureTime frame
90 day modified Rankin score;

Secondary

MeasureTime frame
door to needle time;24-hour vascular recanalization rate (including thrombolysis and thrombectomy);Data omission rate;Remedial endovascular treatment rate;Early neurological deterioration rate (24-hour NIHSS score = 4 points compared to pre-treatment);36 hour incidence of symptomatic intracranial hemorrhage;90 day all-cause mortality rate;Adverse events and serious adverse events;

Countries

China

Contacts

Public ContactJinglin Yuan

Beijing Daxing District People's Hospital

miao3252003@163.com+86 134 2625 2069

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026